Revance Therapeutics (RVNC) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update
August 5, 2021 4:05 PM EDT- Q2 revenue for the RHA® Collection of dermal fillers of $17.0 million
- Aesthetic accounts increased to over 2,000 from over 1,500 in the prior quarter
- Fintech payment processing volume run-rate increased to over $500 million in Q2
- U.S. Food and Drug Administration (FDA) pre-approval inspection initiated in June, with approval of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines anticipated in second half 2021
- Conference call and webcast today at 4:30 p.m. ET
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a... More
